Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Rhea-AI Summary

Tiziana Life Sciences (Nasdaq: TLSA) announced on December 15, 2025 that its Chief Executive Officer, Ivor Elrifi, purchased 163,400 shares of Tiziana common stock in the open market.

Following this transaction, the CEO's total purchased shares amount to 357,848. The purchase was executed on the open market and reflects an insider buy by the company's chief executive.

Positive

• CEO purchased 163,400 shares in open market
• CEO total purchased shares now 357,848

Negative

• None.

Key Figures

CEO share purchase 163,400 shares Open-market purchase by Chief Executive Officer

Total CEO purchased shares 357,848 shares Cumulative purchased Tiziana common stock held by CEO

Market Reality Check

$1.59 Last Close

Volume Volume 947,360 is 3.23x the 20-day average, indicating unusually active trading ahead of this insider purchase news. high

Technical Price 1.78 is trading above the 200-day MA at 1.64, reflecting a constructive longer-term trend.

Peers on Argus 6 Up

Biotech peers in scanners (e.g., KYTX up 22.77%, VOR up 9.07%) showed strong upside, while sector_context peers were mixed. With sector-wide moves not uniformly aligned, TLSA’s action appeared more stock-specific around company developments.

Common Catalyst One key peer, KYTX, had positive clinical trial news, suggesting some stock-specific catalysts within biotech rather than a broad sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 12	Clinical trial update	Positive	+3.5%	Phase 2 Alzheimer’s trial enrollment and first dosing timing for intranasal foralumab.
Dec 02	Strategic spinout plan	Positive	+0.0%	Plan to spin out IL-6 asset TZLS-501 into a separate listed company.
Nov 25	Clinical trial update	Positive	+5.2%	ALS Phase 2 trial for intranasal foralumab accepted into Healey ALS MyMatch Program.
Nov 13	Conference presentation	Neutral	-7.3%	Jefferies conference corporate overview highlighting pipeline and clinical milestones.
Oct 29	Conference participation	Neutral	-3.1%	BIO-Europe 2025 presentation and partnering focus on intranasal foralumab programs.

Pattern Detected

Positive clinical and pipeline updates often saw aligned gains, while conference or corporate updates without immediate catalysts more frequently diverged with negative or flat price reactions.

Recent Company History

Over the past few months, Tiziana has highlighted its immunomodulation pipeline across multiple milestones. Clinical progress included Phase 2 work for intranasal foralumab in ALS on Nov 25, 2025 and an early Alzheimer’s Phase 2 trial update on Dec 12, 2025, both followed by positive price reactions. In contrast, conference appearances on Nov 13 and Oct 29, 2025 and the Dec 2, 2025 IL-6 spinout plan drew flat-to-negative reactions, underscoring stronger market focus on concrete clinical catalysts.

Market Pulse Summary

This announcement highlights an open-market purchase of 163,400 shares by the Chief Executive Officer, bringing his total purchased holdings to 357,848 shares. In the context of recent clinical milestones for intranasal foralumab across Alzheimer’s and ALS, the transaction adds another data point to the company’s evolving story. Investors may monitor future insider activity, additional trial updates, and any changes in corporate strategy as key indicators of how the program and overall business continue to develop.

Key Terms

intranasal foralumab medical

"with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody"

Intranasal foralumab is an experimental antibody medication given as a spray or drops into the nose that aims to change how the immune system behaves rather than attack a virus directly. Investors care because results from trials, safety findings, and regulatory decisions determine whether this approach can become a marketed therapy, affecting a company’s future sales, development costs and competitive position — similar to betting on a new product that could reshape a company’s revenue stream.

monoclonal antibody medical

"intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

AI-generated analysis. Not financial advice.

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 163,400 shares of Tiziana common stock in the open market. This brings his current purchased shares total to 357,848.

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120

[2] https://www.pnas.org/doi/10.1073/pnas.2309221120

FAQ

What did Tiziana (TLSA) announce on December 15, 2025 about insider buying?

Tiziana announced its CEO, Ivor Elrifi, purchased 163,400 shares in the open market, bringing his total purchased shares to 357,848.

How many Tiziana (TLSA) shares did CEO Ivor Elrifi own after the December 15, 2025 purchase?

After the purchase the CEO's purchased shares totalled 357,848.

Was the CEO purchase of Tiziana (TLSA) shares a private transaction or open market trade?

The purchase was executed in the open market.

Does the December 15, 2025 filing for Tiziana (TLSA) state the purchase price per share?

No price per share was disclosed; the announcement only states the number of shares purchased.

Could the CEO purchase on December 15, 2025 affect Tiziana (TLSA) stock price?

Insider buys can signal executive confidence; the announcement reports the 163,400 share open-market purchase but does not project price impact.

Where can investors find the official disclosure of Ivor Elrifi's Tiziana (TLSA) share purchase?

Investors can review the company's public disclosures and Nasdaq filings for official transaction details and timing.